Plasmacytoid Dendritic Cells Depletion and Elevation of IFN-γ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 16 01 2021
accepted: 03 03 2021
entrez: 12 4 2021
pubmed: 13 4 2021
medline: 20 4 2021
Statut: epublish

Résumé

SARS-CoV-2 occurs in the majority of children as COVID-19, without symptoms or with a paucisymptomatic respiratory syndrome, but a small proportion of children develop the systemic Multi Inflammatory Syndrome (MIS-C), characterized by persistent fever and systemic hyperinflammation, with some clinical features resembling Kawasaki Disease (KD). With this study we aimed to shed new light on the pathogenesis of these two SARS-CoV-2-related clinical manifestations. We investigated lymphocyte and dendritic cells subsets, chemokine/cytokine profiles and evaluated the neutrophil activity mediators, myeloperoxidase (MPO), and reactive oxygen species (ROS), in 10 children with COVID-19 and 9 with MIS-C at the time of hospital admission. Patients with MIS-C showed higher plasma levels of C reactive protein (CRP), MPO, IL-6, and of the pro-inflammatory chemokines CXCL8 and CCL2 than COVID-19 children. In addition, they displayed higher levels of the chemokines CXCL9 and CXCL10, mainly induced by IFN-γ. By contrast, we detected IFN-α in plasma of children with COVID-19, but not in patients with MIS-C. This observation was consistent with the increase of ISG15 and IFIT1 mRNAs in cells of COVID-19 patients, while ISG15 and IFIT1 mRNA were detected in MIS-C at levels comparable to healthy controls. Moreover, quantification of the number of plasmacytoid dendritic cells (pDCs), which constitute the main source of IFN-α, showed profound depletion of this subset in MIS-C, but not in COVID-19. Our results show a pattern of immune response which is suggestive of type I interferon activation in COVID-19 children, probably related to a recent interaction with the virus, while in MIS-C the immune response is characterized by elevation of the inflammatory cytokines/chemokines IL-6, CCL2, and CXCL8 and of the chemokines CXCL9 and CXL10, which are markers of an active Th1 type immune response. We believe that these immunological events, together with neutrophil activation, might be crucial in inducing the multisystem and cardiovascular damage observed in MIS-C.

Sections du résumé

Background
SARS-CoV-2 occurs in the majority of children as COVID-19, without symptoms or with a paucisymptomatic respiratory syndrome, but a small proportion of children develop the systemic Multi Inflammatory Syndrome (MIS-C), characterized by persistent fever and systemic hyperinflammation, with some clinical features resembling Kawasaki Disease (KD).
Objective
With this study we aimed to shed new light on the pathogenesis of these two SARS-CoV-2-related clinical manifestations.
Methods
We investigated lymphocyte and dendritic cells subsets, chemokine/cytokine profiles and evaluated the neutrophil activity mediators, myeloperoxidase (MPO), and reactive oxygen species (ROS), in 10 children with COVID-19 and 9 with MIS-C at the time of hospital admission.
Results
Patients with MIS-C showed higher plasma levels of C reactive protein (CRP), MPO, IL-6, and of the pro-inflammatory chemokines CXCL8 and CCL2 than COVID-19 children. In addition, they displayed higher levels of the chemokines CXCL9 and CXCL10, mainly induced by IFN-γ. By contrast, we detected IFN-α in plasma of children with COVID-19, but not in patients with MIS-C. This observation was consistent with the increase of ISG15 and IFIT1 mRNAs in cells of COVID-19 patients, while ISG15 and IFIT1 mRNA were detected in MIS-C at levels comparable to healthy controls. Moreover, quantification of the number of plasmacytoid dendritic cells (pDCs), which constitute the main source of IFN-α, showed profound depletion of this subset in MIS-C, but not in COVID-19.
Conclusions
Our results show a pattern of immune response which is suggestive of type I interferon activation in COVID-19 children, probably related to a recent interaction with the virus, while in MIS-C the immune response is characterized by elevation of the inflammatory cytokines/chemokines IL-6, CCL2, and CXCL8 and of the chemokines CXCL9 and CXL10, which are markers of an active Th1 type immune response. We believe that these immunological events, together with neutrophil activation, might be crucial in inducing the multisystem and cardiovascular damage observed in MIS-C.

Identifiants

pubmed: 33841438
doi: 10.3389/fimmu.2021.654587
pmc: PMC8033149
doi:

Substances chimiques

CXCL10 protein, human 0
CXCL9 protein, human 0
Chemokine CXCL10 0
Chemokine CXCL9 0
IFNG protein, human 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

654587

Informations de copyright

Copyright © 2021 Caldarale, Giacomelli, Garrafa, Tamassia, Morreale, Poli, Timpano, Baresi, Zunica, Cattalini, Moratto, Chiarini, Cannizzo, Marchetti, Cassatella, Taddio, Tommasini and Badolato.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Immunity. 2004 Jul;21(1):107-19
pubmed: 15345224
Int J Rheum Dis. 2018 Jan;21(1):20-25
pubmed: 29105346
J Pediatric Infect Dis Soc. 2021 Aug 14;10(6):706-713
pubmed: 33180935
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
BMJ Paediatr Open. 2021 Feb 4;5(1):e000894
pubmed: 34192188
Front Cell Infect Microbiol. 2020 May 26;10:249
pubmed: 32528903
Front Biosci. 2008 Jan 01;13:2400-7
pubmed: 17981721
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
Trends Immunol. 2001 Feb;22(2):83-7
pubmed: 11286708
Exp Biol Med (Maywood). 2021 Jan;246(1):5-9
pubmed: 32972235
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063
pubmed: 32293098
Front Immunol. 2020 Jun 26;11:1161
pubmed: 32676075
Immunol Lett. 2017 Apr;184:112-114
pubmed: 28219676
J Nephrol. 2020 Dec;33(6):1373-1376
pubmed: 32981025
J Cell Mol Med. 2019 Aug;23(8):5119-5127
pubmed: 31210423
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Euro Surveill. 2020 May;25(18):
pubmed: 32400362
Nat Rev Immunol. 2020 Aug;20(8):453-454
pubmed: 32546853
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Clin Exp Immunol. 2003 Sep;133(3):448-53
pubmed: 12930373
J Exp Med. 1992 Aug 1;176(2):587-92
pubmed: 1380064
Int J Mol Sci. 2021 Jan 20;22(3):
pubmed: 33498183
Eur J Pediatr. 2002 Oct;161(10):538-41
pubmed: 12297900
Immunology. 2013 Oct;140(2):153-67
pubmed: 23909285
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Methods Mol Biol. 2020;2087:243-260
pubmed: 31728997
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
Circ Res. 2019 Aug 2;125(4):470-488
pubmed: 31518165
Cell Host Microbe. 2020 Jun 10;27(6):870-878
pubmed: 32464097
Biotechniques. 2002 Jun;32(6):1372-4, 1376, 1378-9
pubmed: 12074169
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Emerg Med Pract. 2020 Apr 16;22(5 Suppl):CD1-CD2
pubmed: 32297727
Clin Infect Dis. 2021 Nov 2;73(9):e3110-e3112
pubmed: 32985664
Lancet Infect Dis. 2020 Nov;20(11):e276-e288
pubmed: 32818434
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Med. 1999 Aug;5(8):919-23
pubmed: 10426316
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Science. 2004 Mar 5;303(5663):1529-31
pubmed: 14976261
N Engl J Med. 2020 Jul 23;383(4):347-358
pubmed: 32598830
Blood. 2007 Feb 1;109(3):1131-7
pubmed: 16985170
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Front Immunol. 2020 Oct 20;11:580987
pubmed: 33193384
Lancet Child Adolesc Health. 2020 Oct;4(10):790-794
pubmed: 32828177
J Clin Invest. 2020 Nov 2;130(11):5942-5950
pubmed: 32701511
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
EBioMedicine. 2020 Aug;58:102925
pubmed: 32745993
J Exp Med. 2011 Nov 21;208(12):2367-74
pubmed: 22084408
Front Cell Infect Microbiol. 2020 Sep 30;10:561366
pubmed: 33102253
Circulation. 2020 Aug 4;142(5):429-436
pubmed: 32418446
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1074-1080
pubmed: 32790663
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059

Auteurs

Francesca Caldarale (F)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
"Angelo Nocivelli" Institute of Molecular Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Mauro Giacomelli (M)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
"Angelo Nocivelli" Institute of Molecular Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Emirena Garrafa (E)

Department of Molecular and translational Medicin and Clinical Chemistry Laboratory ASST Spedali Civili, Brescia, Italy.

Nicola Tamassia (N)

Section of General Pathology, Department of Medicine, University of Verona, Verona, Italy.

Alessia Morreale (A)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
"Angelo Nocivelli" Institute of Molecular Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Piercarlo Poli (P)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
"Angelo Nocivelli" Institute of Molecular Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Silviana Timpano (S)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
"Angelo Nocivelli" Institute of Molecular Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Giulia Baresi (G)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
"Angelo Nocivelli" Institute of Molecular Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Fiammetta Zunica (F)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
"Angelo Nocivelli" Institute of Molecular Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Marco Cattalini (M)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
"Angelo Nocivelli" Institute of Molecular Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Daniele Moratto (D)

Flow Cytometry & Clinical Chemistry Laboratory, ASST Spedali Civili, Brescia, Italy.

Marco Chiarini (M)

Flow Cytometry & Clinical Chemistry Laboratory, ASST Spedali Civili, Brescia, Italy.

Elvira Stefania Cannizzo (ES)

Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.

Giulia Marchetti (G)

Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.

Marco Antonio Cassatella (MA)

Section of General Pathology, Department of Medicine, University of Verona, Verona, Italy.

Andrea Taddio (A)

Pediatric Department, IRCCS Burlo Garofolo, Trieste, Italy.

Alberto Tommasini (A)

Pediatric Department, IRCCS Burlo Garofolo, Trieste, Italy.

Raffaele Badolato (R)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
"Angelo Nocivelli" Institute of Molecular Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH